Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
editas medicine
gene editing
life sciences
national blog main
san francisco blog main
3
×
boston
crispr
crispr-cas9
national top stories
san francisco top stories
abbvie
advaxis
agios therapeutics
aimmune therapeutics
alder biopharmaceuticals
alexander hardy
allergan
alzheimer's disease
andrew oxtoby
babies
base editing
boulder/denver blog main
boulder/denver top stories
branden moriarty
breakup
bridge bio pharma
broad institute
cas13
ceo
clinical hold
clinical study
clinical trials
combination
commissioner
congress
crispr therapeutics
cynthia collins
What
editas
3
×
cas
crispr
editing
gene
medicine
abbvie
alliance
beam
big
bio
biotech
bosley's
bosley’s
bridge
bucks
ceo
crime
departure
editor
exit
exits
experimental
founders
genetic
gotten
guiding
harvard
jump
katrine
mass
medicines
moves
pact
partnership
personnel
precise
pruning
research
returning
Language
unset
Current search:
editas
×
" san francisco blog main "
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M